Our Code of Business Conduct underpins our commitment to integrity and sets out fundamental rules for interacting with others as we drive our business forward. Supporting policies, standard operating procedures and guidelines provide more detail on how our high-level commitments should be applied in practice. Compliance with the Code is mandatory, all Idorsia employees are trained on its implementation.
Clinical trials are essential to the development of innovative medicines. Idorsia is committed to the highest quality and ethical standards in all our clinical research. Our trials are performed in accordance with internationally accepted guidelines, and protocols are evaluated by independent review boards and ethics committees prior to study initiation. We are also dedicated to enhancing public health through responsible clinical trial information transparency which respects our proprietary information, patients’ privacy, laws and regulations. In addition to our existing clinical trial disclosure activities, we are committed to implementing the Principles for Responsible Clinical Trial Data Sharing jointly issued by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA).
California Health & Safety Code
Section 119402 of the California Health & Safety Code requires a pharmaceutical company to adopt a Comprehensive Compliance Program that is in accordance with the U.S. Department of Health and Human Services, Office of Inspector General’s (“OIG”) “Compliance Program Guidance for Pharmaceutical Manufacturers” (“OIG Compliance Guidance”), and include policies for complying with the Pharmaceutical Research and Manufacturers of America Code on Interactions with Health Care Professionals (“PhRMA Code”). The following two documents relate to these requirements.
More information
Learn more about our responsibilities on our corporate website.
Whistleblower hotline
- USA: (833) 222-3891 (anonymous reporting channel)
- Outside USA: +41 58 844 0106
Compassionate Use
Kindly note that only qualified physicians may register patients for an Idorsia Discretionary Compassionate Use Program. A patient who is not eligible for or unable to participate in a respective clinical trial may be eligible for Idorsia’s Discretionary Compassionate Use Program subject to the following conditions:
- The underlying disease or condition of the patient is seriously debilitating or life threatening.
- There are no approved alternative therapies available to the patient.
- The patient is not eligible for enrollment in any applicable, ongoing clinical trial for the relevant condition and the concerned investigational product.
- The treating responsible physician reasonably expects that the patient will benefit from the treatment without undue safety risks.
- It can be assured that providing the investigational drug will not interfere with the initiation, conduct or completion of clinical investigations that could support marketing approval or otherwise compromise the potential development of the investigational drug.
- The treating physician will agree in writing to comply with Idorsia’s requirements in terms of medical criteria, safety reporting, drug supply/use, and protection of Idorsia proprietary information and/or intellectual property.
- The request must be made by the patient’s treating physician, unsolicited by Idorsia or any other individual or organization.
In addition to these criteria, Idorsia will assess other factors to determine whether access to Idorsia’s Discretionary Compassionate Use Program can be provided to the patient, including available clinical data supporting an anticipated acceptable benefit–risk effect for the proposed use, any potential implications on the overall clinical development of the medicine, and the possible supply of the requested investigational drug.
Submission of a request:
Information about Idorsia’s active clinical trials is available on www.clinicaltrials.gov. Requests for access to an Idorsia investigational drug via its Discretionary Compassionate Use Program must be made by a qualified physician by sending a message via the contact form including the investigational treatment name and the patient’s disease or condition. To maintain the patient's privacy, no personally identifiable information must be included (no personal data of the patient such as e.g. patient's name, social security number, address, date of birth) in the request. The request will be acknowledged within 2 business days upon receipt.